Welcome to our dedicated page for Metagenomi Therapeutics SEC filings (Ticker: MGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Metagenomi Therapeutics, Inc. (Nasdaq: MGX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public biotechnology issuer focused on in vivo genome editing and precision genetic medicines. These filings offer detailed information on financial performance, pipeline progress, and key corporate events related to its proprietary gene editing toolbox and programs such as MGX-001 for hemophilia A.
Metagenomi, Inc. files current reports on Form 8-K to announce material events, including quarterly financial results, business updates, and new preclinical data. For example, Form 8-K filings reference press releases that discuss non-human primate data for MGX-001, strategic pipeline prioritization, and corporate presentations. These 8-Ks often furnish exhibits containing full press releases and investor slide decks, which can provide additional scientific and strategic context.
Investors can also review quarterly reports on Form 10-Q and other periodic filings, which the company notes in its press releases, for more comprehensive discussions of research and development activities, collaboration revenue, operating expenses, and risk factors. As an emerging growth company, Metagenomi discloses its status and related accounting elections within these documents.
On Stock Titan, MGX filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize lengthy documents such as 10-Qs and 10-Ks, highlight key sections, and clarify technical language. Users can quickly identify items related to in vivo genome editing programs, collaboration agreements, capital allocation, and organizational changes. In addition, Form 4 and other insider transaction reports, when filed, can be reviewed to monitor trading activity by directors and officers.
This page is a central resource for analyzing Metagenomi Therapeutics’ official disclosures, from financial results and pipeline data to governance updates, supporting deeper research into the MGX investment and its genome editing platform.
Metagenomi Therapeutics, Inc. (MGX) discloses that Brian Thomas has filed a Schedule 13G reporting beneficial ownership of 2,762,142 shares of its common stock, representing 7.3% of the class as of June 30, 2026.
The position includes 2,433,969 shares held of record and 328,173 shares underlying stock options exercisable within 60 days of June 30, 2026. Based on 37,777,105 shares outstanding as of August 6, 2026, he has sole voting and dispositive power over all 2,762,142 reported shares.
Metagenomi Therapeutics, Inc. (MGX) reported that officer Matthew Wein, the company’s General Counsel, Compliance Officer and Corporate Secretary, had 358 shares of common stock sold on September 8, 2026 at $1.1584 per share. The shares were automatically sold to satisfy tax withholding obligations upon vesting of restricted stock units and are stated not to be a volitional trade. Following this transaction, Wein held 126,133 shares of Metagenomi common stock directly.
Metagenomi Therapeutics, Inc. (MGX) reported that President and Chief Executive Officer and director Jian Irish sold 2,140 shares of common stock on September 8, 2026 at $1.1584 per share. After this sale, she held 375,393 shares of common stock directly.
According to the filing, these shares were automatically sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on April 1, 2024 and April 1, 2025, and the transaction "does not represent a volitional trade" by Jian Irish. The filing also notes additional indirect holdings of common stock in two 2023 irrevocable trusts, for which she disclaims beneficial ownership except to the extent of her pecuniary interest.
Metagenomi Therapeutics, Inc. (MGX) reported that its Chief Financial Officer, Pamela Wapnick, had 1,911 shares of common stock sold on September 8, 2026 at $1.1584 per share. The company states these shares were automatically sold to satisfy tax withholding obligations upon vesting of restricted stock units and do not represent a volitional trade. Following this transaction, Wapnick directly holds 206,580 shares of common stock.
Metagenomi Therapeutics, Inc. reported continued operating losses as it advances its in vivo genome-editing pipeline and Ionis collaboration. For the quarter ended June 30, 2026, collaboration revenue was a negative $0.3 million, down from $8.5 million a year earlier, largely due to an April 2026 modification of the Ionis agreement that triggered a $2.6 million negative cumulative catch-up adjustment and lower current-period activity.
Quarterly research and development expense was $22.5 million and general and administrative expense was $6.0 million, together slightly below the prior year as the company reprioritized programs while increasing external R&D services. Net loss for the quarter widened to $27.5 million, and the six‑month net loss reached $50.5 million, or $1.34 per share basic and diluted.
As of June 30, 2026, Metagenomi held $39.0 million in cash and cash equivalents and $81.6 million in available-for-sale marketable securities, for $120.7 million of liquidity, plus $4.4 million of restricted cash. Management believes these resources are sufficient to fund the current operating plan for at least 12 months and notes an unused $75.0 million at-the-market equity program. Deferred revenue of $11.2 million reflects remaining obligations under the Ionis collaboration.
Metagenomi Therapeutics, Inc. reported second quarter 2026 results and business updates, highlighting progress on its lead in vivo genome editing program MGX-001 for hemophilia A. IND-enabling studies are expected to be completed by the end of the third quarter of 2026, with an IND filing planned for the fourth quarter of 2026 and, subject to regulatory clearance, clinical trial initiation in 2027.
Cash, cash equivalents and available-for-sale marketable securities totaled $120.7 million as of June 30, 2026, and the company anticipates this cash runway will support operations through the fourth quarter of 2027. For the quarter, collaboration revenue was $(0.257) million, R&D expenses were $22.5 million, G&A expenses were $6.0 million, and net loss was $27.5 million, or $(0.73) per share.
Second quarter updates also noted that two Metagenomi posters, including one with extensive non-human primate data supporting MGX-001, received Top Poster Awards at the 2026 ISTH Congress. The company continues to evaluate additional disease indications for its large gene integration system for protein replacement via gene insertion.
Metagenomi Therapeutics director Reid Laurence received a grant of stock options covering 17,400 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They vest on the earlier of one year from the grant date or the company’s 2027 annual stockholder meeting, subject to his continued service.
Metagenomi Therapeutics director Dere Willard H received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. These options vest in full on the earlier of one year after the grant date or the company’s 2027 annual stockholder meeting, provided he continues serving the company through that vesting date.
Metagenomi Therapeutics director Eric Bjerkholt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and give the right to buy 21,000 shares once vested.
The options vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company’s 2027 annual meeting of stockholders, provided he continues serving the company through that vesting date. Following this grant, his reported holdings of this option award total 21,000 derivative securities.
Metagenomi Therapeutics, Inc. director Juergen Eckhardt received a grant of stock options covering 21,000 shares of common stock. The options have an exercise price of $1.23 per share and expire on June 8, 2036. They will vest and become exercisable on the earlier of the one-year anniversary of the grant date or the company's 2027 annual meeting of stockholders, subject to his continued service with the company. After this award, he holds 21,000 stock options directly.